Portrait of a senior woman standing outdoors on a holiday. Senior woman wearing a backpack and jacket standing during a trekking trip.

Bringing hope through science

Oncopeptides AB (publ) is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. We are science driven, entrepreneurial, and committed to bringing innovation to our patients. Our vision is to bring hope to patients through passionate people, innovative science and transformative drugs.

Read more about Oncopeptides

Oncopeptalks on congresses and CD selection

June 27, 2024 – CEO Sofia and Oncopeptides’ congress chief discusses the importance of attending industry events, and Sofia gives her perspective on the recent SPiKE news.

See the new episode of Oncopeptalks

First SPiKE candidate drug selected

June 27, 2024 – The first candidate drug based on the company’s unique platform for Small Polypeptide based innate Killer Engagers (SPiKE) has been selected.

Click here to read more including questions and answers for investors

Company news

Our Journey - the history of Oncoptpeptides

Our Journey - updated version

June 27, 2024

Watch Our Journey - the story of Oncopeptides, recently updated with a new section where Sofia Heigis, CEO of Oncopeptides, shares her vision for the future of the company.

Read more

First patients in Spain to be treated with Pepaxti

May 27, 2024

Oncopeptides has announced that the first Spanish hospital will soon begin treating patients with Pepaxti.

Read more
Oncopeptides launches Spanish website.

Oncopeptides launches Spanish website

May 2, 2024

As part of the company´s ongoing efforts to increase our visibility in Spain and strengthen relationships with the Spanish community, Oncopeptides recently launched www.oncopeptides.es.

Read more

Science news

Oncopeptides selects first candidate drug from its SPiKE platform

June 27, 2024

Oncopeptides recently announced that the first candidate drug based on the company´s unique platform for Small Polypeptide based innate Killer Engagers (SPiKE) has been selected.

Read more

Oncopeptides presents new data highlighting treatment benefits of Pepaxti in high-risk multiple myeloma patients at the COMy Congress

May 16, 2024

Oncopeptides today announces that new scientific data on melflufen, branded in Europe as Pepaxti, has been accepted at the 10th annual World Congress on Controversies in Multiple Myeloma (COMy), to be held on May 23-26.

Read more

Oncopeptides’ PORT study shows peripheral administration of Pepaxti being equally safe as central venous administration

March 1, 2024

Oncopeptides today announces that a new article analyzing scientific data on melflufen, marketed in Europe as Pepaxti, was recently published in the peer-reviewed medical journal Clinical Lymphoma, Myeloma and Leukemia.

Read more

Investor news

Oncopeptalks on congresses and CD selection

June 27, 2024

Sofia and Oncopeptides’ congress chief discusses the importance of attending industry events, and Sofia gives her perspective on the recent SPiKE news.

Read more
CFO Henrik Bergentoft presenting at Aktiespararna June 2024

Oncopeptides presented at Aktiespararna event

June 12, 2024

Oncopeptides CFO Henrik Bergentoft recently presented the company at the Aktiedagen event in Stockholm. See the presentation (in Swedish only)

Read more
Sofia Heigis CEO presentation at the AGM 2024

CEO presentation from recent Annual General Meeting

June 5, 2024

Watch the presentation from CEO Sofia Heigis at the recent Annual General Meeting (AGM) held on May 31 in Stockholm.

Read more

Press release - June 28, 2024

Number of shares and votes in Oncopeptides

Read press release

Upcoming events

2024-07-15 - 2024-08-13

Silent Period

Other

2024-08-14

Interim Report Q2 2024

Report

2024-10-08 - 2024-11-06

Silent Period

Other

CEO Sofia Heigis - Oncopeptides AB

Released May 30, 2024

Oncopeptides publishes Q1 report 2024

Read report

Download

“Launch ready in Spain in record time”

CEO Sofia Heigis

 

See the Webcast

 

Webcast presentation as pdf (updated)

 

Correct map for slide 21 – on geographic expansion

 

 

For further information, please contact:

David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68

 

Oncopeptides AB Q2 interim report 2024 will be published August 14, 2024

Senior Hispanic man in wheelchair, with adult son

Vision of Oncopeptides

”Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”

Read more about Oncopeptides

Oncopeptides value words inside the logotype

Cultures & Values

We are a science driven, entrepreneurial company, committed to bringing innovation to patients with an unmet medical need, and improving their lives.

Read more

Journey of innovation

Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden’s leading cancer researchers and cancer research institutions.

Read more about our history

Picture Annual Report 2023

Released April 22, 2024

Oncopeptides publishes the 2023 Annual Report

Read report

Download

“Accelerating toward profitability”

CEO Sofia Heigis

 

For further information, please contact:

David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68

Oncopeptides via e-mail